EndoRon Medical

What EndoRon Medical does

EndoRon Medical Ltd. is an Israel-based, privately-held medical device company developing transcatheter endovascular anchoring solutions for the aortic continuum. The company is organized around two core investigational products: Aortodock, a self-expanding nitinol frame with staples that engage on balloon expansion to deliver calcium-independent anchoring for transcatheter aortic valve replacement (TAVR) in aortic regurgitation patients; and Aortoseal, an endograft fastening system that simultaneously deploys staples circumferentially through the graft and into the aortic wall to mimic hand-sutured open-repair anastomosis in endovascular aneurysm repair (EVAR). Both products target anatomies that current commercial devices are poorly suited to handle, specifically non-calcified AR anatomy and complex proximal neck AAA anatomy, where 40%–60% of EVAR candidates fall outside device instructions for use.

The company is pre-revenue: devices are explicitly stated to be limited to investigational use, no pricing is publicly disclosed, and there are no commercial sales or named customers. Capital to date totals roughly $10M in Series A equity (July 2024, led by Sofinnova Partners with EIC Fund participation), a €2.5M EIC Accelerator grant (2023), an earlier ~$2.6M EIC equity tranche (June 2022), and a prior ~$5M Sofinnova round (December 2021). Go-to-market is structured as enterprise field sales targeting hospitals and vascular surgery departments in Europe (with US also noted), engaging vascular surgeons and cardiac teams through medical conferences, a Scientific Advisory Board, and direct hospital procurement channels once regulatory clearance is achieved.

Leadership is a notable asset: the Chairman is Dr. Jacques Seguin (CoreValve founder, sold to Medtronic for over $800M); the Scientific Advisory Board includes Dr. Juan Parodi (forefather of EVAR); the CCSO is Sunny Choh, PhD (ex-Medtronic Senior Director, Structural Heart & Aortic); the COO is Chen Ludomirski Kaufman; and the founders include a physiotherapist-turned-CEO (Ronit Harpaz), a CTO with 30+ years of cardiovascular device R&D (Eyal Teichman), and a CMO who heads vascular surgery at Hadassah Medical Center (Dr. Ron Karmeli). The company employs 1–10 people and is headquartered in Kfar Saba, Israel.

Name

EndoRon Medical

Legal name

Endoron Medical Ltd.

Website

https://www.endoronmedical.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

EndoRon Medical is an Israeli medical device company developing transcatheter endovascular anchoring devices—Aortodock for TAVR and Aortoseal for EVAR—targeting patients with aortic regurgitation and complex abdominal aortic aneurysms not well served by existing devices. Company is pre-revenue and investigational.

Ownership category

akta.pro rank

Product category

Endovascular Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts (HLAHAFAF)

akta.pro secondary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Endovascular medical devices
• Transcatheter valve replacement
• Aortic aneurysm repair
• Endograft fastening devices
• Vascular surgery devices

Headquarters

HQ city

Kfar Saba

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Pre-revenue medical device company developing endovascular anchoring solutions. Revenue will be generated from sales of Aortodock and Aortoseal devices to hospitals and vascular surgery centers for use in TAVR and EVAR procedures respectively. Devices are currently limited to investigational use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

EndoRon Medical develops transcatheter endovascular anchoring solutions for aortic procedures. Its Aortodock product is a self-expanding nitinol frame with staples that delivers calcium-independent anchoring for transcatheter aortic valve replacement (TAVR) in patients with aortic regurgitation. Its Aortoseal product is an endograft fastening system using a multi-stapling mechanism that mimics hand-suturing of open repair for endovascular aneurysm repair (EVAR) in patients with complex proximal neck anatomies. Both devices are currently limited to investigational use and targeted at hospitals and vascular surgery centers.

Product overview

EndoRon Medical offers a portfolio of transcatheter endovascular anchoring solutions consisting of two core products: Aortodock, a transcatheter valve docking solution for TAVR procedures that provides calcium-independent anchoring for aortic regurgitation patients; and Aortoseal, an endograft fastening solution for EVAR procedures that delivers 360-degree simultaneous fixation and sealing through a multi-stapling mechanism. Both products are designed to address anatomies that are challenging for existing devices, expanding treatment options across the aortic continuum.

Differentiator

Problem solved

Functional benefit

Brands

• Aortoseal: Next generation endosuturing device for EVAR (Endovascular Aneurysm Repair) - a long-lasting fixation and sealing system for stent grafts along the aortic continuum.
• Aortodock

Products and services

• Aortodock A transcatheter valve docking solution engineered to deliver calcium-independent anchoring and stability for transcatheter aortic valve replacement (TAVR). Aortodock is a self-expanding nitinol frame with staples that engage with balloon expansion, creating a stable landing zone independent of calcium burden, annular shape, or dilation. The steerable delivery system permits implant recapturing and repositioning for precise placement, enabling treatment of low-to-no calcium aortic regurgitation and aortic stenosis anatomies that currently cannot be reliably addressed with existing TAVR devices. Devices are limited to investigational use.
• Aortoseal An endograft fastening solution for endovascular aneurysm repair (EVAR) that provides long-lasting fixation and sealing through a smart multi-stapling mechanism. Aortoseal deploys multiple staples simultaneously through the graft and into the aortic wall, creating a true anastomosis that mimics hand-suturing of open surgical repair. Staples are distributed circumferentially for radial and longitudinal fixation with transmural attachment to the adventitial layer, designed to reduce migration, endoleaks, and reinterventions across all aortic segments, particularly in patients with short, angulated, or irregular proximal necks. Devices are limited to investigational use.

Quantifiable outcome

• 40%-60% of EVAR candidates present with anatomies outside device instructions for use due to complex proximal necks
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Hadassah Medical CenterminorStrategic or Co-development PartnerDr. Ron Karmeli, Co-Founder & CMO of Endoron Medical, serves as Head of the Vascular Surgery Department at Hadassah Medical Center in Jerusalem.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Global leader in structural heart (CoreValve/Evolut TAVR franchise) and endovascular aneurysm repair (Endurant). Directly comparable as an incumbent in both of Endoron's target procedure categories and a likely strategic acquirer of differentiated enabling technology.
• Edwards Lifesciences: TAVR market leader via the Sapien platform and a major structural-heart incumbent. Comparable to Endoron as the dominant player in transcatheter aortic valve replacement, the procedure Endoron aims to expand into non-calcified AR.
• W. L. Gore & Associates: Manufacturer of the Gore Excluder and other EVAR/TEVAR endograft systems. Comparable to Endoron as a long-standing EVAR incumbent whose device the Aortoseal is explicitly designed to complement in hostile neck anatomy.
• Terumo Aortic (Bolton Medical): Acquired Bolton Medical to build a thoracic and abdominal aortic stent-graft business (Relay, Treo). Comparable as a broad EVAR/TEVAR incumbent whose endografts compete in the same AAA fixation and sealing space as Aortoseal.
• Artivion (formerly CryoLife): Cardiovascular and vascular surgery company with stent-graft and tissue valve products. Comparable to Endoron as a structural heart and aortic device company with overlapping clinical call points in vascular surgery.
• Boston Scientific: Major structural-heart and endovascular player, having acquired Veniti and Aptus EndoSystems for endovascular anchoring technology. Comparable to Endoron both as a competitor in aortic devices and as a likely acquirer of enabling anchoring/stapling IP.
• Cook Medical: Long-standing manufacturer of endovascular aortic stent-graft systems (Zenith). Comparable as a broad EVAR/TEVAR incumbent whose devices address the same AAA patient population that Endoron's Aortoseal targets.

Direct peers

• Endologix: Pure-play EVAR/AAA device company (AFX, Ovation). Direct peer to Endoron's Aortoseal program given shared focus on abdominal aortic aneurysm repair endografts and sealing/fixation challenges in hostile neck anatomy.
• Lombard Medical: Developer of endovascular aortic aneurysm repair systems (Altura). Direct peer to Endoron's Aortoseal as a focused EVAR device manufacturer addressing proximal neck fixation and sealing in AAA repair.
• JenaValve Technology: Developer of transcatheter aortic valve systems specifically designed for aortic regurgitation patients who lack calcium for anchoring — directly overlapping Endoron's Aortodock clinical and technical thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eismea

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EndoRon Medical